Other analysts have also issued research reports about the stock. Cowen restated a buy rating and issued a $213.00 price target on shares of Sarepta Therapeutics in a research note on Sunday, March 31st. Nomura lifted their price target on shares of Sarepta Therapeutics from $205.00 to $230.00 and gave the stock a buy rating in a research note on Thursday, February 28th. JMP Securities restated a buy rating and issued a $270.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, February 27th. Cantor Fitzgerald restated a buy rating on shares of Sarepta Therapeutics in a research note on Friday, February 22nd. Finally, Citigroup lifted their price target on shares of Sarepta Therapeutics from $188.00 to $201.00 and gave the stock a buy rating in a research note on Friday, March 1st. Twenty-one investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus price target of $201.71.
NASDAQ SRPT opened at $129.88 on Friday. Sarepta Therapeutics has a 52 week low of $95.21 and a 52 week high of $165.87. The company has a debt-to-equity ratio of 0.35, a quick ratio of 11.15 and a current ratio of 12.17. The firm has a market cap of $9.63 billion, a PE ratio of -23.79 and a beta of 1.96.
In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director now owns 21,717 shares in the company, valued at $2,606,040. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.60% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in SRPT. Janus Henderson Group PLC increased its stake in Sarepta Therapeutics by 44.9% during the first quarter. Janus Henderson Group PLC now owns 2,666,043 shares of the biotechnology company’s stock valued at $317,766,000 after purchasing an additional 826,449 shares during the last quarter. FMR LLC grew its position in shares of Sarepta Therapeutics by 6.9% during the fourth quarter. FMR LLC now owns 10,565,177 shares of the biotechnology company’s stock worth $1,152,977,000 after acquiring an additional 677,947 shares during the last quarter. OppenheimerFunds Inc. grew its position in shares of Sarepta Therapeutics by 505.6% during the first quarter. OppenheimerFunds Inc. now owns 768,868 shares of the biotechnology company’s stock worth $91,642,000 after acquiring an additional 641,904 shares during the last quarter. Norges Bank bought a new position in shares of Sarepta Therapeutics during the fourth quarter worth about $57,891,000. Finally, venBio Select Advisor LLC grew its position in shares of Sarepta Therapeutics by 35.1% during the fourth quarter. venBio Select Advisor LLC now owns 1,275,000 shares of the biotechnology company’s stock worth $139,141,000 after acquiring an additional 331,500 shares during the last quarter.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Article: What factors cause inflation to rise?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.